Related Experiment Video
Updated: May 26, 2026
Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice
Published on: October 3, 2010
Medulloblastoma and primitive neuroectodermal tumors
Roger J Packer1, Tobey Macdonald, Gilbert Vezina
1The George Washington University, Washington, DC, USA. rpacker@cnmc.org
Abstract:
Medulloblastomas and sPNETs remain highly problematic tumors to treat. Prognosis has improved over the past two decades, but many children who survive treatment have significant long-term sequelae. The improvements in outcome have been due to advances in surgical techniques, the wider use of chemotherapy, and the more judicious use of radiotherapy. For further improvements,the recent impressive discoveries concerning molecular mechanisms of embryonal tumor origin, development,and growth will need to be translated into molecularly based, risk-adapted therapy.
Insights
Medulloblastomas and primitive neuroectodermal tumors (sPNETs) are challenging childhood cancers. Future treatment advances for these embryonal tumors depend on translating molecular discoveries into targeted therapies.
Area of Science:
- Pediatric Oncology
- Neuro-oncology
- Cancer Genomics
Background:
- Medulloblastomas and supratentorial primitive neuroectodermal tumors (sPNETs) represent significant challenges in pediatric oncology.
- While survival rates have improved, survivors often face severe long-term health issues (sequelae).
- Current treatment relies on surgery, chemotherapy, and radiotherapy, with outcomes gradually improving over two decades.
Purpose of the Study:
- To highlight the persistent challenges in treating medulloblastomas and sPNETs.
- To emphasize the need for novel therapeutic strategies beyond current standards of care.
- To underscore the importance of integrating molecular insights into clinical practice.
Main Methods:
- Review of current treatment modalities and outcomes for medulloblastomas and sPNETs.
- Analysis of factors contributing to recent improvements in patient prognosis.
- Discussion of the potential impact of molecular biology discoveries on future therapies.
Main Results:
- Significant progress has been made in treating these embryonal tumors over the past 20 years.
- Improvements are attributed to surgical advancements, increased chemotherapy use, and refined radiotherapy.
- Despite progress, substantial challenges and long-term sequelae persist for childhood cancer survivors.
Conclusions:
- Further improvements in treating medulloblastomas and sPNETs necessitate a shift towards molecularly informed, risk-adapted therapeutic approaches.
- Translating recent discoveries on the molecular mechanisms of embryonal tumor development is crucial.
- Personalized medicine based on tumor molecular profiles holds promise for better outcomes and reduced long-term toxicity.
Related Concept Videos
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
01:30Neurulation